The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.14%	-0.05%

2020	The Medicines Company Announces Board Changes	CI
2020	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI

Capitalization	6.79B 6.46B 5.99B 5.33B 9.62B 576B 10.66B 74.59B 27.53B 237B 25.49B 24.94B 1,033B	P/E ratio 2017	-2.79x	P/E ratio 2018	-11.4x
Enterprise value	7.34B 6.99B 6.48B 5.76B 10.4B 623B 11.52B 80.65B 29.77B 256B 27.57B 26.97B 1,117B	EV / Sales 2017	55.1x	EV / Sales 2018	319x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

The Medicines Company Announces Board Changes	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P TMI Index	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P 1000	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P Global BMI Index	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P Composite 1500	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from S&P Biotechnology Select Industry Index	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Biotechnology Index	20-01-06	CI
The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Composite Index	20-01-06	CI
Novartis AG completed the acquisition of The Medicines Company.	20-01-02	CI
World share markets rally on revived trade hopes; dollar gains	19-11-25	RE
World share markets rally on revived trade hopes; dollar gains	19-11-25	RE

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases	Apr. 19	AQ
The Medicines Company : Announces Effective Date of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022	20-01-07	AQ
The Medicines Company : Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024	20-01-06	BU
MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	20-01-06	AQ
MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-01-06	AQ

The Medicines Company Stock

Equities

MDCO

US5846881051

Pharmaceuticals

Valuation: The Medicines Company

Latest news: The Medicines Company

Press Releases: The Medicines Company

News in other languages: The Medicines Company

Managers and Directors: The Medicines Company

Generic Pharmaceuticals

Financials

Company Profile

Medicines : Novartis bringt Übernahme von US-Biotech-Firma in trockene Tücher	20-01-06
Les fusions-acquisitions soutenues par la vigueur du marché américain en 2019	19-12-30
EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...	19-12-05
Des marchés dopés à l'optimisme	19-11-26
Point marchés-Les actions profitent des espoirs sur le commerce et des M&A	19-11-25

Director	Title	Age	Since
Krishna Gorti IRC	Investor Relations Contact	-	-
Stephen M. Rodin LAW	General Counsel	47	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.18%	+0.08%	+46.46%	+138.23%	51.08B
OTSUKA HOLDINGS CO., LTD.	+0.32%	-3.64%	+54.93%	+115.51%	31.33B
SANDOZ GROUP AG	-0.18%	-2.67%	+40.01%	-	18.98B
CIPLA LIMITED	-0.94%	-3.48%	+19.37%	+62.68%	13.98B
ZYDUS LIFESCIENCES LIMITED	-0.84%	-0.04%	+52.56%	+110.68%	11.65B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
ONO PHARMACEUTICAL CO., LTD.	-0.03%	-2.16%	-34.00%	-37.39%	5.32B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.03%	-1.59%	+4.45%	+20.22%	5.23B
GLENMARK PHARMACEUTICALS LIMITED	+1.88%	-0.32%	+93.81%	+203.82%	5.04B
Average	+0.03%	-0.93%	+34.70%	+87.68%	15.51B
Weighted average by Cap.	+0.00%	-0.80%	+42.43%	+111.45%

	2017	2018
Net sales	44.79M 42.63M 39.51M 35.14M 63.43M 3.8B 70.3M 492M 182M 1.56B 168M 165M 6.81B	6.14M 5.84M 5.41M 4.82M 8.69M 521M 9.63M 67.42M 24.89M 214M 23.04M 22.55M 933M
Net income	-708M -674M -625M -556M -1B -60.11B -1.11B -7.78B -2.87B -24.68B -2.66B -2.6B -108B	-123M -117M -109M -96.62M -174M -10.45B -193M -1.35B -499M -4.29B -462M -452M -18.73B
Net Debt	498M 474M 439M 391M 705M 42.25B 781M 5.47B 2.02B 17.35B 1.87B 1.83B 75.7B	552M 525M 487M 433M 781M 46.83B 866M 6.06B 2.24B 19.23B 2.07B 2.03B 83.91B